Therapy Areas: Cardiovascular
Moderna to Supply Additional Doses of COVID-19 Vaccine Per New Gavi Deal
29 October 2021 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) has inked an agreement with Gavi, the Vaccine Alliance to supply up 116.5m doses of Moderna's COVID-19 vaccine to be delivered in the second quarter of 2022, the company said.

The exercise of these options for additional doses represents an increase from an earlier agreement for 60 m doses of Moderna's COVID-19 vaccine that was communicated earlier this year.

As per the advance purchase agreement signed on behalf of the COVAX Facility, Gavi continues to retain the option to procure 233m additional doses in 2022 for a potential total of 500 m doses between 2021 and 2022 under the agreement.

All doses are offered at Moderna's lowest tiered price, in line with the company's global access commitments.

This agreement covers the 92 Gavi COVAX Advance Market Commitment low- and middle-income countries.

COVAX is a global initiative co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels.

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA, to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.

Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.

Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.

Moderna has been named a top biopharmaceutical employer by Science for the past seven years.